ASMI disappointed on S3 advertising recommendation

white pills and tablets: GMiA
ASMI says that the Expert Panel report on the regulatory framework for medicines and medical devices falls short in its recommendation to retain restrictions on the advertising of S3 medicines. ASMI’s Executive Director, Deon Schoombie, welcomed the Panel’s recommendations on the scheduling framework for non-prescription medicines, saying that suggested changes are long overdue. “However, while

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Picking up Gonorrhoea: SaveTheScript winners announced
Next Babies who snore under-diagnosed, researchers find